US Patent 7,834,059: Nepafenac Ophthalmic Suspension Claims, Scope, Expiry and Patent Landscape

US Patent 7,834,059 protects a narrowly defined method of treating ophthalmic inflammatory disorders with a 0.1% nepafenac topical ophthalmic suspension. The claims require the full formulation, specified excipient concentrations, a pH of 7.3 to 7.7, topical administration to a human patient, and treatment of an ophthalmic inflammatory disorder.

The patent is a formulation and method-of-use patent, not a broad composition patent covering every nepafenac product. Its practical relevance is greatest for products that reproduce the claimed Nevanac-type formulation or use an equivalent formulation in the claimed therapeutic setting.

What does US Patent 7,834,059 claim?

The patent has two materially overlapping independent claims.

Claim	Claimed subject matter	Principal legal limitation
1	Method of treating an ophthalmic inflammatory disorder by topical administration	Requires administration of a composition consisting of nine specified components and a defined pH
2	Improvement in a method using an aqueous nepafenac suspension	Requires the same composition and pH, framed as an improvement to an existing nepafenac-suspension treatment

The claimed formulation contains:

Component	Required concentration or condition
Nepafenac	0.1% w/v
Carbomer	0.5% w/v
Tyloxapol	0.01% w/v
Sodium chloride	0.4% w/v
Mannitol	2.4% w/v
pH-adjusting agent	Quantity sufficient to produce pH 7.3-7.7
Benzalkonium chloride	0.005% w/v
Edetate disodium	0.01% w/v
Purified water	Remainder or specified aqueous vehicle

The claim language tracks the formulation used in Nevanac, Alcon's nepafenac ophthalmic suspension. The FDA-approved labeling identifies nepafenac 0.1% ophthalmic suspension and lists the same principal inactive ingredients, including carbomer 974P, sodium chloride, tyloxapol, mannitol, edetate disodium and benzalkonium chloride.[2]

How narrow is the scope of the claims?

The scope is narrow because the claims combine composition, concentration, dosage form, administration route, patient type and treatment purpose.

A product or method would generally need to satisfy all material limitations to fall within literal claim scope. The principal limitations are:

The active ingredient must be nepafenac.
Nepafenac must be present at 0.1% w/v.
Carbomer must be present at 0.5% w/v.
Tyloxapol must be present at 0.01% w/v.
Sodium chloride must be present at 0.4% w/v.
Mannitol must be present at 2.4% w/v.
Benzalkonium chloride must be present at 0.005% w/v.
Edetate disodium must be present at 0.01% w/v.
The vehicle must include purified water.
The formulation must have a pH between 7.3 and 7.7.
The composition must be administered topically.
The patient must be human.
The treatment must address an ophthalmic inflammatory disorder.

A formulation containing nepafenac at 0.1% but using a different viscosity enhancer, preservative, tonicity agent or pH range would not literally satisfy the claim. The same is true for a composition containing 0.5% carbomer but a materially different concentration of mannitol or sodium chloride.

What does "consisting of" mean in these claims?

"Consisting of" is a closed transition. It generally excludes unlisted ingredients that materially alter the claimed composition, subject to conventional interpretation of incidental impurities and ingredients that do not defeat the closed formulation definition.

This wording creates a significant design-around constraint. A competing product containing an additional surfactant, buffer, preservative, stabilizer or other formulation excipient could argue that it does not meet the literal composition limitation. The strength of that argument would depend on whether the additional ingredient is considered part of the claimed composition and how a court interprets the claim in light of the specification and prosecution history.

The phrase does not eliminate all infringement risk. A patentee could assert infringement under the doctrine of equivalents, although the closed formulation language and the prosecution history would be important limitations on that theory.

Does the patent cover Nevanac?

The claims are directed to the formulation and use of the 0.1% nepafenac ophthalmic suspension marketed as Nevanac. The formulation described in the FDA label corresponds closely to the claimed ingredient profile and concentration ranges.[2]

That correspondence creates a strong product-to-claim mapping:

Nevanac product characteristic	Claim requirement
Nepafenac ophthalmic suspension	Nepafenac aqueous suspension
0.1% nepafenac	0.1% w/v nepafenac
Carbomer 974P	0.5% w/v carbomer
Tyloxapol	0.01% w/v
Sodium chloride	0.4% w/v
Mannitol	2.4% w/v
Benzalkonium chloride	0.005% w/v
Edetate disodium	0.01% w/v
pH-controlled aqueous vehicle	pH 7.3-7.7

The patent therefore appears commercially aligned with the branded product's formulation. The claims do not, however, automatically cover every generic nepafenac 0.1% suspension. A generic product must be compared against the approved product's formulation, its ANDA disclosure, and the precise claim limitations.

What patent protects the formulation, and what patents protect nepafenac more broadly?

US Patent 7,834,059 should be distinguished from earlier nepafenac patents and from other patents that may cover ophthalmic uses, formulations or manufacturing processes.

Formulation patent

US 7,834,059 is directed to the specific aqueous nepafenac suspension and its use in treating ophthalmic inflammatory disorders.[1] Its strongest commercial function is to protect the excipient system used in the marketed formulation.

Earlier nepafenac and ophthalmic-use patents

Earlier patents in the nepafenac family and related ophthalmic patent families may address:

Nepafenac as an active pharmaceutical ingredient.
Conversion of nepafenac to amfenac in ocular tissue.
Treatment of postoperative ocular inflammation.
Treatment of pain and inflammation associated with cataract surgery.
Ophthalmic formulations containing nepafenac.
Dosage regimens and administration after ophthalmic surgery.

Those patents must be analyzed separately. A patent directed to the active compound may have expired before the formulation patent. A use patent may also have a different expiration date and may be limited to a particular indication or dosing regimen.

Orange Book-listed patents

The FDA Orange Book is the principal source for determining which patents an NDA holder has listed against an approved drug product and the expiration dates reported for those patents.[3] The relevant analysis should distinguish:

Patents listed for Nevanac 0.1% ophthalmic suspension.
Patents listed for other nepafenac products.
Patents covering formulation, method of use or both.
Whether a listed patent has expired, been delisted or remains enforceable.
Whether the patent is relevant to the specific ANDA product and proposed labeling.

A patent's presence in the Orange Book does not establish validity or infringement. It creates an FDA-regulated certification framework for ANDA applicants.

When does US Patent 7,834,059 expire?

US Patent 7,834,059 issued on November 16, 2010.[1] Its expected term is generally calculated under the modern 20-year patent-term framework from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension.

Public patent records identify the patent as having a 2027-era expiration date. The operative date should be taken from the USPTO Patent Center record and any current Orange Book listing because patent-term adjustment can change the nominal expiration date.[1][3]

Event	Date or status
Patent issued	November 16, 2010
Patent type	Utility patent
Core subject	Nepafenac ophthalmic formulation and treatment method
Expected expiration	2027, subject to PTA and terminal-disclaimer review
Pediatric exclusivity	Must be checked separately in the Orange Book
Current commercial relevance	Formulation protection for 0.1% nepafenac suspension

The patent does not receive a new term merely because the product remains commercially successful. Any additional FDA exclusivity would arise under the regulatory exclusivity provisions, not from the patent itself.

What Paragraph IV challenges affect this patent?

An ANDA applicant seeking approval before expiration of an Orange Book-listed patent may file a Paragraph IV certification asserting that the patent is invalid, unenforceable or will not be infringed.[4] The NDA holder may then bring an infringement action within 45 days, triggering a statutory stay of FDA approval that can last up to 30 months, subject to statutory exceptions.

For US 7,834,059, the relevant litigation question is not whether a company has filed an ANDA for nepafenac generally. It is whether the ANDA applicant certified against this specific patent and whether the NDA holder asserted the patent.

Potential Paragraph IV positions include:

The ANDA formulation does not contain one or more claimed excipients at the specified concentration.
The ANDA product falls outside the pH range.
The product does not contain the exact claimed composition.
The method of use is not within the proposed labeling.
The claims are anticipated or obvious over earlier nepafenac formulations.
The claims are indefinite because of the closed composition language or the pH-adjusting-agent limitation.
The patent is unenforceable based on prosecution conduct, if supported by the record.

The formulation's narrow limitations make non-infringement a potentially strong ANDA strategy. The countervailing risk is that a generic manufacturer may need to match the reference listed drug closely to establish pharmaceutical equivalence and obtain approval, which can reduce formulation flexibility.

Is there biosimilar risk for nepafenac?

No. Nepafenac is a chemically synthesized small-molecule drug, not a biologic subject to the biosimilar pathway under the Public Health Service Act.

Competitive entry occurs through the ANDA pathway for a generic drug, not through a biosimilar application. Relevant regulatory mechanisms include:

Abbreviated New Drug Application approval.
Paragraph I, II, III or IV patent certifications.
30-month stay litigation.
Section viii statements for method-of-use patents.
Therapeutic-equivalence designation, if FDA requirements are met.

The principal competition risk is therefore generic nepafenac ophthalmic suspension, not biosimilar substitution.

What generic entry risks exist?

Generic entry risk depends on whether the applicant can obtain approval with a formulation that is pharmaceutically equivalent but falls outside the patent claims.

Low-risk design-around characteristics

A generic may reduce literal infringement risk by changing one or more of the following:

Carbomer concentration.
Mannitol concentration.
Sodium chloride concentration.
Tyloxapol concentration.
Preservative system.
Chelating agent.
pH.
Use of an alternative viscosity modifier or surfactant.

The product must still satisfy FDA requirements for sameness, stability, performance, sterility, particle size, viscosity, redispersibility and ophthalmic safety.

Higher-risk characteristics

Risk increases where the generic:

Reproduces all nine listed components.
Uses the same concentrations.
Maintains pH between 7.3 and 7.7.
Uses the same formulation architecture as Nevanac.
Includes labeling that expressly directs treatment of the patented ophthalmic inflammatory conditions.

A generic can also face induced-infringement allegations if its labeling encourages physicians to practice a patented method, even where the product itself is not directly administered by the manufacturer.

How strong is the patent estate?

US 7,834,059 has moderate formulation strength and narrower blocking power.

Factor	Assessment
Claim type	Method claims tied to a defined formulation
Breadth	Narrow
Product correlation	High for the Nevanac-type formulation
Design-around potential	Meaningful
Dependence on exact concentrations	High
Dependence on pH	High
Small-molecule generic exposure	High
Biosimilar exposure	Not applicable
Manufacturing barrier	Limited unless process patents also apply
Litigation leverage	Strongest against close formulation copies

The patent is more valuable as a targeted product-protection asset than as a broad barrier to all nepafenac products. A competitor using the same active ingredient in a materially different formulation may avoid literal infringement while still requiring substantial development work to demonstrate pharmaceutical equivalence and ophthalmic performance.

What manufacturing and IP barriers remain after patent expiry?

Patent expiry does not eliminate regulatory and technical barriers. A generic applicant must still address:

Sterile ophthalmic manufacturing.
Particle-size control for nepafenac.
Suspension uniformity and redispersibility.
Container-closure compatibility.
Preservative effectiveness.
Ocular tolerability.
Stability across the proposed shelf life.
Bioequivalence or other FDA-supported equivalence requirements.
Manufacturing validation and quality-system compliance.

Process patents, equipment claims, container patents and trade secrets may create additional barriers, but those rights are separate from US 7,834,059 and cannot be inferred from the two claims supplied.

What litigation and settlement issues should be reviewed?

A complete commercial assessment should separate four records:

USPTO prosecution history for claim amendments, examiner objections and terminal disclaimers.
FDA Orange Book patent listings and delisting history.
Federal court complaints, claim-construction rulings, settlements and consent judgments.
ANDA applicant certifications and FDA approval dates.

The claim's use of "consisting of" makes prosecution history particularly important. If the applicant narrowed the composition to obtain allowance, that history could limit later reliance on the doctrine of equivalents. Any settlement agreement may also impose a launch date before patent expiry without admitting validity or infringement.

No reliable conclusion about a specific Paragraph IV settlement, litigation judgment or generic launch date follows from the claim text alone.

Key Takeaways

US 7,834,059 is a narrow formulation-and-method patent for a 0.1% nepafenac ophthalmic suspension.
The claims require exact concentrations for carbomer, tyloxapol, sodium chloride, mannitol, benzalkonium chloride and edetate disodium.
The formulation must have a pH of 7.3 to 7.7 and must be administered topically to a human patient.
The "consisting of" language materially narrows the claims and supports formulation-based design-around strategies.
The patent closely corresponds to the Nevanac formulation described in FDA labeling.
Nepafenac faces generic, not biosimilar, competition.
The patent has a 2027-era expected expiration, subject to USPTO patent-term adjustment and Orange Book verification.
Generic risk is highest for a formulation that reproduces the listed ingredients, concentrations and pH.
Earlier compound, ophthalmic-use and formulation patents must be analyzed separately from US 7,834,059.
Patent validity, infringement, Orange Book listing status and litigation outcomes cannot be determined from the two claims alone.

FAQs

Does US 7,834,059 cover all nepafenac eye drops?

No. It covers a defined composition and its topical use. A nepafenac product with different excipients, concentrations or pH may fall outside the literal claims.

Can a generic use nepafenac at 0.1% without infringing?

Potentially. The generic would need to avoid at least one material limitation while satisfying FDA requirements for pharmaceutical equivalence and approval.

Is carbomer 974P expressly required?

The claims recite 0.5% carbomer. The commercial product uses carbomer 974P. Whether a particular carbomer grade satisfies the claim depends on the claim construction and specification.

Does changing the pH avoid the patent?

A pH outside 7.3 to 7.7 may avoid literal infringement of the pH limitation, but the product could still face an equivalents argument depending on the prosecution history and technical facts.

Does the patent cover treatment of non-inflammatory eye diseases?

Not on the face of the claims. The claimed method is directed to treating ophthalmic inflammatory disorders in a human patient.

References

United States Patent No. 7,834,059, "Ophthalmic compositions containing nepafenac," issued November 16, 2010, United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Nevanac (nepafenac ophthalmic suspension) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and 30-month stays. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING OCULAR INFLAMMATION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	052252	⤷ Start Trial
Austria	E476200	⤷ Start Trial
Australia	2005311738	⤷ Start Trial
Brazil	PI0518904	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,834,059

Which drugs does patent 7,834,059 protect, and when does it expire?

Summary for Patent: 7,834,059